Grants per year
Personal profile
Research Interests
Pathogenesis & treatment of pituitary tumors, treatment of diabetic complications
Certifications and Licenses
| Internal Medicine | |
| Endocrinology, Diabetes & Metabolism |
Training Experience
| 1972 | Residency, Hospital of the University of Pennsylvania |
| 1975 | Fellowship, Univ. of CA-Los Angeles Med. Ctr. |
Expertise related to UN Sustainable Devlopment Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MD, University of Pennsylvania
… → 1969
Research interests
- Diabetes
- Endocrinology
- Medicine
- Metabolism
Fingerprint
Dive into the research topics where Mark E Molitch is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot#CRN00808-02: A Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Safety, Pharmacokinetics and Efficacy of CRN00808 in Patients with Acromegaly that are Responders to Octreotide Lar or Landreotide (ACROBAT EVOLVE)
Accelsiors CRO and Consultancy Services Ltd., Crinetics Pharmaceuticals, Inc.
8/6/19 → 8/6/22
Project: Research project
-
Prot#CRN00808-03: An Open Label Exploratory Study to Evaluate the Safety, Pharmacokinetics and Efficacy of CRN00808 in Patients with Acromegaly Treated with Somatostatin Analogue Based Treatment Regimens (ACROBAT EDGE)
Accelsiors CRO and Consultancy Services Ltd., Crinetics Pharmaceuticals, Inc.
8/6/19 → 8/6/22
Project: Research project
-
Prot#CLCI699C2X01B: An Open-label, Multi-Center, Roll-Over Study to Assess Long Term Safety in Patients with Endogenous Cushing’s Syndrome Who Have Completed a Prior Novartis-Sponsored Osilodrostat (LCI699) Study and are Judged by the Investigator to Bene
Novartis Pharmaceuticals Corporation
5/22/19 → 12/31/24
Project: Research project
-
Prot#: ISIS 766720-CS2: A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor) Administered Once Every 28 Days for 16 Weeks i
Medpace Clinical Research LLC, Ionis Pharmaceuticals, Inc.
4/3/19 → 4/3/22
Project: Research project
-
A Pituitary Society update to acromegaly management guidelines
Fleseriu, M., Biller, B. M. K., Freda, P. U., Gadelha, M. R., Giustina, A., Katznelson, L., Molitch, M. E., Samson, S. L., Strasburger, C. J., van der Lely, A. J. & Melmed, S., Feb 2021, In: Pituitary. 24, 1Research output: Contribution to journal › Article › peer-review
Open Access23 Scopus citations -
Comparing Patch vs Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles
Bergenstal, R. M., Johnson, M. L., Aroda, V. R., Brazg, R. L., Dreon, D. M., Frias, J. P., Kruger, D. F., Molitch, M. E., Mullen, D. M., Peyrot, M., Richter, S., Rosenstock, J., Serusclat, P., Vance, C., Weinstock, R. S. & Levy, B. L., 2021, (Accepted/In press) In: Journal of Diabetes Science and Technology.Research output: Contribution to journal › Article › peer-review
-
Correction to: Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results (Pituitary, (2021), 10.1007/s11102-021-01163-2)
Labadzhyan, A., Nachtigall, L. B., Fleseriu, M., Gordon, M. B., Molitch, M., Kennedy, L., Samson, S. L., Greenman, Y., Biermasz, N., Bolanowski, M., Haviv, A., Ludlam, W., Patou, G. & Strasburger, C. J., 2021, (Accepted/In press) In: Pituitary.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands
Fleseriu, M., Molitch, M., Dreval, A., Biermasz, N. R., Gordon, M. B., Crosby, R. D., Ludlam, W. H., Haviv, A., Gilgun-Sherki, Y. & Mathias, S. D., Mar 15 2021, In: Frontiers in Endocrinology. 12, 627711.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
Labadzhyan, A., Nachtigall, L. B., Fleseriu, M., Gordon, M. B., Molitch, M., Kennedy, L., Samson, S. L., Greenman, Y., Biermasz, N., Bolanowski, M., Haviv, A., Ludlam, W., Patou, G. & Strasburger, C. J., 2021, (Accepted/In press) In: Pituitary.Research output: Contribution to journal › Article › peer-review
Open Access